Clinical Trials Logo

Esophageal Adenocarcinoma clinical trials

View clinical trials related to Esophageal Adenocarcinoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03982173 Withdrawn - Clinical trials for Metastatic Colorectal Cancer

Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors

MATILDA
Start date: September 2020
Phase: Phase 2
Study type: Interventional

To determine the efficacy (as measured by overall tumour response rate) of the combination of durvalumab and tremelimumab when given to previously treated patients with solid tumors harboring a high mutational load.

NCT ID: NCT03592407 Withdrawn - Clinical trials for Esophageal Squamous Cell Carcinoma

Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer

Start date: July 1, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects of epacadostat and pembrolizumab and to see how well they work before surgery in treating participants with stage II-III esophageal or gastroesophageal cancer. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of the tumor cells to grow and spread. Giving epacadostat and pembrolizumab before surgery may work better in treating participants with stage II-III esophageal or gastroesophageal cancer.